BRUSA, GIANLUCA
 Distribuzione geografica
Continente #
NA - Nord America 804
EU - Europa 704
AS - Asia 264
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 1.804
Nazione #
US - Stati Uniti d'America 800
GB - Regno Unito 215
SE - Svezia 109
CN - Cina 106
UA - Ucraina 97
VN - Vietnam 93
DE - Germania 92
IT - Italia 59
IN - India 35
IE - Irlanda 34
FR - Francia 28
RU - Federazione Russa 24
EE - Estonia 15
ZA - Sudafrica 13
JP - Giappone 9
CH - Svizzera 8
TG - Togo 7
CZ - Repubblica Ceca 6
JO - Giordania 6
SC - Seychelles 6
IR - Iran 5
CA - Canada 4
ID - Indonesia 4
GR - Grecia 3
HR - Croazia 3
RO - Romania 3
SG - Singapore 3
BE - Belgio 2
BG - Bulgaria 2
FI - Finlandia 2
NL - Olanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AU - Australia 1
CI - Costa d'Avorio 1
CL - Cile 1
EG - Egitto 1
KR - Corea 1
LB - Libano 1
NG - Nigeria 1
Totale 1.804
Città #
Southend 187
Fairfield 93
Chandler 86
Jacksonville 70
Ashburn 68
Dong Ket 55
Wilmington 55
Seattle 47
Houston 42
Woodbridge 39
Princeton 38
Dublin 33
Ann Arbor 32
Cambridge 22
Nanjing 19
Padova 19
Westminster 19
New York 18
Beijing 14
Berlin 14
Jinan 13
Verona 10
Falls Church 9
Medford 9
Mülheim 9
Saint Petersburg 8
Shenyang 8
Tokyo 8
Lomé 7
Milan 7
Amman 6
Bern 6
Boardman 5
Changsha 5
Hebei 5
Mahé 5
San Diego 5
Taizhou 5
Andover 4
Bologna 4
Bühl 4
Hangzhou 4
Jakarta 4
Nanchang 4
Norwalk 4
Toronto 4
Dearborn 3
Fuzhou 3
Guangzhou 3
Jiaxing 3
Kunming 3
Tianjin 3
Zhengzhou 3
Brussels 2
Des Moines 2
Fremont 2
Kuban 2
Lausanne 2
Ningbo 2
Sofia 2
Taiyuan 2
Turin 2
Abeokuta 1
Abidjan 1
Albany 1
Ancona 1
Ardabil 1
Ballina 1
Florence 1
Groningen 1
Hanover 1
Helsinki 1
Kettering 1
Lappeenranta 1
Leawood 1
Los Angeles 1
Mumbai 1
Olalla 1
Olinda 1
Phoenix 1
Pune 1
Redwood City 1
San Francisco 1
Seoul 1
Tappahannock 1
Timis 1
Vancouver 1
Zagreb 1
Zanjan 1
Zhoushan 1
Totale 1.199
Nome #
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia 155
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 147
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 132
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 110
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. 107
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 105
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 98
IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia 97
The p210BCR-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene 96
Modulation of apoptotic signalling by 9-hydroxystearic acid in osteosarcoma cells 92
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 88
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 85
GENOMIC UNBALANCES ASSOCIATED WITH THE RESISTANCE TO IONIZING RADIATIONS OF A HUMAN OSTEOSARCOMA CELL LINE (SAOS) DETECTED BY COMPARATIVE GENOMIC HYBRIDIZATION (CGH-BASED TECHNIQUE) 77
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 77
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 75
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 75
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 74
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 71
COVALENT MODIFICATIONS OF HISTONE H4 NH2-TERMINAL TAILS ASSOCIATED WITH P210 BCR-ABL TYROSINE KINASE 69
Totale 1.830
Categoria #
all - tutte 4.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.290


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020471 86 9 12 32 38 42 51 64 50 29 19 39
2020/2021312 59 25 3 25 5 19 2 19 18 14 26 97
2021/2022366 37 9 32 29 30 23 8 19 14 22 69 74
2022/2023347 51 46 25 36 18 32 6 13 64 7 27 22
2023/2024109 4 15 1 23 5 27 9 9 5 4 4 3
Totale 1.830